This award endorses the innovative alliance of high quality food ingredients and nutritional research

SOLACTIS™ is a new, high added value nutritional ingredient which has been recently launched on the European digestive health ingredients market. The development of this particularly effective product, offering both a prebiotic and a transit regularization effect, marks a milestone in research and innovation in health and nutrition, and responds to the needs of consumers who place digestive health at the forefront of their expectations.

SOLACTIS™: a tasty milk-based innovation, with applications in a very wide range of products.
SOLACTIS™ is a nutritional ingredient based on GalactoFructose, which gives a soft and sweet taste to food.
Easily combinable, in powder or syrup form, with a wide variety of pleasant flavors, it can be integrated into a very wide range of foods including yoghurts and fermented milk products, biscuits, beverages, food supplements and baby food.
Exceptional resistance to temperature and pH makes SOLACTIS™ one of the few digestive health ingredients available until now for use in such a wide range of products.
The specificity of SOLACTIS™ lies also in its dairy origin, being based on GalactoFructose, derived from the heat treatment of milk by simple lactose isomerization.

SOLACTIS™: a major scientific innovation for proven health benefits
SOLACTIS™ is an indigestible carbohydrate that both balances the intestinal flora and regulates transit. On the one hand it encourages development of the natural intestinal flora present in the colon by selectively stimulating the growth and activity of certain bacteria, in particular Bifidobacteria, on the other it reduces transit time and facilitates the proper functioning of the small intestine and colon, thereby improving digestion comfort and general well-being. For these reasons the development of SOLACTIS™ represents a veritable scientific innovation in the service of health.
These promises were approved by the Belgian Federal Health Department (SPF Santé) in 2006, have been recommended by the Italian public health authorities and are right now being examined by the European authorities.

SOLACTIS™: of economic interest to the food processing industry
SOLACTIS™ can act at low daily doses. It has proven its prebiotic effectiveness from just 0.65 grams of GalactoFructose, and benefits from the double claim 'prebiotic + transit regulation' at a recommended daily dose of 2.5 g, whereas other prebiotics require a daily consumption of 5 grams for the prebiotic claim alone. These reduced doses represent a genuine economic advantage on the European market.
Health, and digestive health in particular, are at the heart of Solvay’s concerns, making them a real driver of nutritional research. With this innovation to its credit, the Group is continuing its research to extend the health benefits of SolactisTM and develop new products.

Solvay in brief
SOLVAY GROUP is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs more than 29,000 people in 50 countries.
In 2008, its consolidated sales amounted to EUR 9.5 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals.
Further information atwww.solactis.com and www.solvay.fr

The Frost & Sullivan Digestive Health Ingredient of the Year Award is given to companies which demonstrate the excellence of their research by developing products for industrial use.